Role of Src signal transduction pathways in scatter factor-mediated cellular protection

J Biol Chem. 2009 Mar 20;284(12):7561-77. doi: 10.1074/jbc.M807497200. Epub 2008 Dec 1.

Abstract

Scatter factor (SF) (hepatocyte growth factor) is a pleiotrophic cytokine that accumulates in tumors, where it may induce invasion, angiogenesis, and chemoresistance. We have studied the mechanisms by which SF and its receptor (c-Met) protect cells against the DNA-damaging agent adriamycin (ADR) as a model for chemoresistance of SF/c-Met-overexpressing tumors. Previous studies identified a phosphatidylinositol 3-kinase/c-Akt/Pak1/NF-kappaB cell survival pathway in DU-145 prostate cancer and Madin-Darby canine kidney epithelial cells. Here we studied Src signaling pathways involved in SF cell protection. Src enhanced basal and SF stimulated NF-kappaB activity and SF protection against ADR, in a manner dependent upon its kinase and Src homology 3 domains; and endogenous Src was required for SF stimulation of NF-kappaB activity and cell protection. The ability of Src to enhance SF stimulation of NF-kappaB activity was due, in part, to its ability to stimulate Akt and IkappaB kinase activity; and Src-mediated stimulation of NF-kappaB was due, in part, to a Rac1/MKK3/6/p38 pathway and was Akt-dependent. SF caused the activation of Src and the Rac1 effector Pak1. Furthermore, SF induced activating phosphorylations of MKK3, MKK6, and p38 within the c-Met signalsome in an Src-dependent manner. The NF-kappaB-inducing kinase was found to act downstream of TAK1 (transforming growth factor-beta-activated kinase 1) as a mediator of SF- and Src-stimulated NF-kappaB activity. Finally, the Src/Rac1/MKK3/6/p38 and Src/TAK1/NF-kappaB-inducing kinase pathways exhibited cross-talk at the level of MKK3. These findings delineate some novel signaling pathways for SF-mediated resistance to ADR.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / pharmacology
  • Cell Line, Tumor
  • Dogs
  • Doxorubicin / pharmacology
  • Drug Resistance, Neoplasm*
  • Hepatocyte Growth Factor / metabolism*
  • Humans
  • I-kappa B Kinase / metabolism
  • MAP Kinase Kinase 3 / metabolism
  • MAP Kinase Kinase 6
  • MAP Kinase Kinase Kinases / metabolism
  • MAP Kinase Signaling System*
  • Male
  • NF-kappa B / metabolism
  • Neoplasms / metabolism*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Proto-Oncogene Proteins c-met / metabolism
  • Proto-Oncogene Proteins pp60(c-src) / metabolism*
  • p38 Mitogen-Activated Protein Kinases / metabolism
  • rac1 GTP-Binding Protein / metabolism
  • src Homology Domains

Substances

  • Antibiotics, Antineoplastic
  • HGF protein, human
  • NF-kappa B
  • RAC1 protein, human
  • Hepatocyte Growth Factor
  • Doxorubicin
  • Proto-Oncogene Proteins c-met
  • Proto-Oncogene Proteins pp60(c-src)
  • Proto-Oncogene Proteins c-akt
  • I-kappa B Kinase
  • p38 Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinases
  • MAP kinase kinase kinase 7
  • MAP Kinase Kinase 3
  • MAP Kinase Kinase 6
  • MAP2K3 protein, human
  • MAP2K6 protein, human
  • rac1 GTP-Binding Protein